Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

Yeast-CEA (GI-6207) is a therapeutic cancer vaccine genetically modified to express recombinant carcinoembryonic antigen (CEA) protein, using heat-killed yeast (Saccharomyces cerevisiae) as a vector. In preclinical studies, yeast-CEA induced a strong immune response to CEA and antitumor responses. P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bilusic, Marijo, Heery, Christopher R., Arlen, Philip M., Rauckhorst, Myrna, Apelian, David, Tsang, Kwong Y., Tucker, Jo A., Jochems, Caroline, Schlom, Jeffrey, Gulley, James L., Madan, Ravi A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2013
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3944709/
https://ncbi.nlm.nih.gov/pubmed/24327292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-013-1505-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge